Alison E. Obr

429 total citations
11 papers, 320 citations indexed

About

Alison E. Obr is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Alison E. Obr has authored 11 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Genetics. Recurrent topics in Alison E. Obr's work include Estrogen and related hormone effects (3 papers), Cytokine Signaling Pathways and Interactions (3 papers) and interferon and immune responses (1 paper). Alison E. Obr is often cited by papers focused on Estrogen and related hormone effects (3 papers), Cytokine Signaling Pathways and Interactions (3 papers) and interferon and immune responses (1 paper). Alison E. Obr collaborates with scholars based in United States, Netherlands and China. Alison E. Obr's co-authors include Dean P. Edwards, Sandra L. Grimm, Teresa L. Wood, John P. Lydon, Sushil Kumar, Raymond B. Birge, Kathleen A. Bishop, J. Wesley Pike, Ke Geng and Mariana S. De Lorenzo and has published in prestigious journals such as Frontiers in Immunology, Molecular Endocrinology and Carcinogenesis.

In The Last Decade

Alison E. Obr

11 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison E. Obr United States 8 144 131 113 67 52 11 320
Carolina Schere‐Levy Argentina 9 131 0.9× 164 1.3× 63 0.6× 47 0.7× 86 1.7× 13 367
Nuša Pristovšek Denmark 8 80 0.6× 300 2.3× 137 1.2× 95 1.4× 36 0.7× 9 451
Adriana C. Rodriguez United States 5 62 0.4× 139 1.1× 97 0.9× 88 1.3× 47 0.9× 7 326
Stephanie J. Ellison United States 7 124 0.9× 222 1.7× 101 0.9× 103 1.5× 76 1.5× 8 460
Maribel Lara‐Chica Spain 10 61 0.4× 169 1.3× 35 0.3× 63 0.9× 35 0.7× 13 301
Aymen Shatnawi United States 10 44 0.3× 210 1.6× 82 0.7× 57 0.9× 29 0.6× 21 355
Katrin P. Guillen United States 9 59 0.4× 107 0.8× 60 0.5× 54 0.8× 33 0.6× 14 221
Janet Dell United States 5 93 0.6× 117 0.9× 124 1.1× 34 0.5× 19 0.4× 5 297
Borbala Katona Sweden 4 53 0.4× 106 0.8× 103 0.9× 21 0.3× 29 0.6× 6 220
Gaëlle Palierne France 8 55 0.4× 266 2.0× 111 1.0× 24 0.4× 33 0.6× 9 359

Countries citing papers authored by Alison E. Obr

Since Specialization
Citations

This map shows the geographic impact of Alison E. Obr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison E. Obr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison E. Obr more than expected).

Fields of papers citing papers by Alison E. Obr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison E. Obr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison E. Obr. The network helps show where Alison E. Obr may publish in the future.

Co-authorship network of co-authors of Alison E. Obr

This figure shows the co-authorship network connecting the top 25 collaborators of Alison E. Obr. A scholar is included among the top collaborators of Alison E. Obr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison E. Obr. Alison E. Obr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Dodd, John H., Robert Jordan, Keith C. Barnett, et al.. (2023). A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans. Frontiers in Immunology. 14. 1083333–1083333. 9 indexed citations
2.
Obr, Alison E., Yun‐Juan Chang, Alexander Lemenze, et al.. (2022). Breast tumor IGF1R regulates cell adhesion and metastasis: alignment of mouse single cell and human breast cancer transcriptomics. Frontiers in Oncology. 12. 990398–990398. 6 indexed citations
3.
Obr, Alison E., et al.. (2020). Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis. ASN NEURO. 12(1). 1665549196–1665549196. 7 indexed citations
4.
Song, Chen, Ning Wang, Tao Qin, et al.. (2019). RNA-binding protein CUGBP1 controls the differential INSR splicing in molecular subtypes of breast cancer cells and affects cell aggressiveness. Carcinogenesis. 41(9). 1294–1305. 13 indexed citations
5.
Obr, Alison E., Sushil Kumar, Yun‐Juan Chang, et al.. (2018). Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment. Breast Cancer Research. 20(1). 138–138. 34 indexed citations
6.
Kumar, Sushil, Viralkumar Davra, Alison E. Obr, et al.. (2017). Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. OncoImmunology. 7(1). e1376155–e1376155. 40 indexed citations
7.
Grimm, Sandra L., R. DeC. Ward, Alison E. Obr, et al.. (2014). A Role for Site-Specific Phosphorylation of Mouse Progesterone Receptor at Serine 191 in Vivo. Molecular Endocrinology. 28(12). 2025–2037. 5 indexed citations
8.
Obr, Alison E., Sandra L. Grimm, Kathleen A. Bishop, et al.. (2013). Progesterone Receptor and Stat5 Signaling Cross Talk Through RANKL in Mammary Epithelial Cells. Molecular Endocrinology. 27(11). 1808–1824. 49 indexed citations
9.
Obr, Alison E. & Dean P. Edwards. (2011). The biology of progesterone receptor in the normal mammary gland and in breast cancer. Molecular and Cellular Endocrinology. 357(1-2). 4–17. 129 indexed citations
10.
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolina Schere‐Levy Breakdown of academic impact, for papers by Nuša Pristovšek Breakdown of academic impact, for papers by Adriana C. Rodriguez Breakdown of academic impact, for papers by Stephanie J. Ellison Breakdown of academic impact, for papers by Maribel Lara‐Chica Breakdown of academic impact, for papers by Aymen Shatnawi Breakdown of academic impact, for papers by Katrin P. Guillen Breakdown of academic impact, for papers by Janet Dell Breakdown of academic impact, for papers by Borbala Katona Breakdown of academic impact, for papers by Gaëlle Palierne
Rankless by CCL
2026